Development of a health economic model to evaluate the cost-effectiveness of roxadustat in treating anemia associated with non-dialysis-dependent chronic kidney disease

References

• Evans M, Lewis RD, Morgan AR, et al. A narrative review of chronic kidney disease in clinical practice: current challenges and future perspectives. Adv Ther. 2022;39(1):33–43. doi: 10.1007/s12325-021-01927-z.
   PubMed Web of Science ®Google Scholar
• Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2005;67(6):2089–2100. doi: 10.1111/j.1523-1755.2005.00365.x.
   PubMed Web of Science ®Google Scholar
• GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020; 395(10225):709–733.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney International. 2012;Suppl. 2:279–335.
   Web of Science ®Google Scholar
• Mikhail A, Brown C, Williams JA, et al. Renal association clinical practice guideline on anaemia of chronic kidney disease. BMC Nephrol. 2017;18(1):345. doi: 10.1186/s12882-017-0688-1.
   PubMed Web of Science ®Google Scholar
• Dmitrieva O, de Lusignan S, Macdougall IC, et al. Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data. BMC Nephrol. 2013;14(1):24. doi: 10.1186/1471-2369-14-24.
   PubMedGoogle Scholar
• Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLOS One. 2014;9(1):e84943. doi: 10.1371/journal.pone.0084943.
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. Anemia and Chronic Kidney Disease 2015. Available from: https://www.kidney.org/atoz/content/what_anemia_ckd.
   Google Scholar
• van Haalen H, Jackson J, Spinowitz B, et al. Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: analysis of multinational real-world data. BMC Nephrol. 2020;21(1):88. doi: 10.1186/s12882-020-01746-4.
   PubMed Web of Science ®Google Scholar
• Hoshino J, Muenz D, Zee J, et al. Associations of hemoglobin levels with health-related quality of life, physical activity, and clinical outcomes in persons with stage 3-5 nondialysis CKD. J Ren Nutr. 2020;30(5):404–414. doi: 10.1053/j.jrn.2019.11.003.
   PubMed Web of Science ®Google Scholar
• Toft G, Heide-Jørgensen U, van Haalen H, et al. Anemia and clinical outcomes in patients with non-dialysis dependent or dialysis dependent severe chronic kidney disease: a Danish population-based study. J Nephrol. 2020;33(1):147–156. doi: 10.1007/s40620-019-00652-9.
   PubMed Web of Science ®Google Scholar
• Thorp ML, Johnson ES, Yang X, et al. Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease. Nephrology (Carlton). 2009;14(2):240–246. doi: 10.1111/j.1440-1797.2008.01065.x.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the dialysis outcomes and practice patterns study (DOPPS). Nephrol Dial Transplant. 2004;19(1):121–132. doi: 10.1093/ndt/gfg458.
   PubMed Web of Science ®Google Scholar
• Eriksson D, Goldsmith D, Teitsson S, et al. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrol. 2016;17(1):97. doi: 10.1186/s12882-016-0312-9.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. NICE guideline [NG203]: chronic kidney disease: assessment and management. 2021. Available from: https://www.nice.org.uk/guidance/ng203.
   Google Scholar
• Gauthier-Loiselle M, Michalopoulos SN, Cloutier M, et al. Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective. J Manag Care Spec Pharm. 2021;27(12):1703–1713. doi: 10.18553/jmcp.2021.27.12.1703.
   PubMed Web of Science ®Google Scholar
• Koury MJ, Haase VH. Anaemia in kidney disease: harnessing hypoxia responses for therapy. Nat Rev Nephrol. 2015;11(7):394–410. doi: 10.1038/nrneph.2015.82.
   PubMed Web of Science ®Google Scholar
• Li QY, Xiong QW, Yao X, et al. Roxadustat: do we know all the answers? Biomol Biomed. 2023;23(3):354–363. doi: 10.17305/bb.2022.8437.
   PubMedGoogle Scholar
• National Institute for Health and Care Excellence. Roxadustat for treating symptomatic anaemia in chronic kidney disease. Technology appraisal guidance [TA807] 2022 [cited 2023 28/06/2023]. Available from: https://www.nice.org.uk/guidance/ta807/chapter/2-Information-about-roxadustat.
   Google Scholar
• European Medicines Agency. Evrenzo European Public Assessment Report 2021 [updated 08 June 2023; cited 2023 15 August 2023]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/evrenzo.
   Google Scholar
• ClinicalTrials.gov. Roxadustat in the treatment of anemia in chronic kidney disease patients not requiring dialysis (ALPS) [10 July 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT01887600.
   Google Scholar
• Shutov E, Sułowicz W, Esposito C, et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrol Dial Transplant. 2021;36(9):1629–1639. doi: 10.1093/ndt/gfab057.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A study of roxadustat for the treatment of anemia in participants with chronic kidney disease and Not Receiving Dialysis [10 July 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT01750190.
   Google Scholar
• Coyne DW, Roger SD, Shin SK, et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney Int Rep. 2021;6(3):624–635. doi: 10.1016/j.ekir.2020.11.034.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Safety and efficacy study of Roxadustat to treat anemia in patients with chronic kidney disease (CKD), not on dialysis [10 July 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT02174627.
   Google Scholar
• Fishbane S, El-Shahawy MA, Pecoits-Filho R, et al. Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study. J Am Soc Nephrol. 2021;32(3):737–755. doi: 10.1681/ASN.2020081150.
   PubMed Web of Science ®Google Scholar
• Provenzano R, Szczech L, Leong R, et al. Efficacy and cardiovascular safety of roxadustat for treatment of anemia in patients with non-dialysis-dependent CKD: pooled results of three randomized clinical trials. Clin J Am Soc Nephrol. 2021;16(8):1190–1200. doi: 10.2215/CJN.16191020.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Roxadustat in the treatment of anemia in chronic kidney disease (CKD) patients, not on dialysis, in comparison to darbepoetin Alfa (dolomites). Available from: https://clinicaltrials.gov/ct2/show/NCT02021318.
   Google Scholar
• Barratt J, Andric B, Tataradze A, et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transplant. 2021;36(9):1616–1628. doi: 10.1093/ndt/gfab191.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Safety and efficacy study of roxadustat (FG-4592) for the treatment of anemia in end-stage Renal disease (ESRD) newly initiated dialysis participants (Himalayas) [10 July 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT02052310.
   Google Scholar
• Provenzano R, Shutov E, Eremeeva L, et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrol Dial Transplant. 2021;36(9):1717–1730. doi: 10.1093/ndt/gfab051.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Safety and efficacy study of roxadustat to treat anemia in patients with chronic kidney disease, on dialysis [10 July 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT02174731.
   Google Scholar
• Fishbane S, Pollock CA, El-Shahawy M, et al. Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study. J Am Soc Nephrol. 2022;33(4):850–866. doi: 10.1681/ASN.2020111638.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Study to evaluate the efficacy and safety of roxadustat in the treatment of anemia in participants with ESRD on stable dialysis [10 July 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT02273726.
   Google Scholar
• Charytan C, Manllo-Karim R, Martin ER, et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney Int Rep. 2021;6(7):1829–1839. doi: 10.1016/j.ekir.2021.04.007.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Roxadustat in the treatment of anemia in end stage renal disease (ESRD) patients on stable dialysis (Pyrenees) [10 July 2023]. Available from: https://clinicaltrials.gov/ct2/show/NCT02278341.
   Google Scholar
• Csiky B, Schömig M, Esposito C, et al. Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, open-label, active-controlled study (PYRENEES). Adv Ther. 2021;38(10):5361–5380. doi: 10.1007/s12325-021-01904-6.
   PubMed Web of Science ®Google Scholar
• KDIGO. Chapter 1: diagnosis and evaluation of anemia in CKD. Kidney Int Suppl (2011). 2012;2(4):288–291.
   PubMed Web of Science ®Google Scholar
• Attema AE, Brouwer WBF, Claxton K. Discounting in economic evaluations. Pharmacoeconomics. 2018;36(7):745–758. doi: 10.1007/s40273-018-0672-z.
   PubMed Web of Science ®Google Scholar
• Yarnoff BO, Hoerger TJ, Simpson SA, et al. The cost-effectiveness of anemia treatment for persons with chronic kidney disease. PLOS One. 2016;11(7):e0157323. doi: 10.1371/journal.pone.0157323.
   PubMed Web of Science ®Google Scholar
• Kind P, Hardman G, Macran S. UK population norms for EQ-5D. Discussion paper 172 cited 2023 15 August 2023]. Available from: https://www.york.ac.uk/che/pdf/DP172.pdf.
   Google Scholar
• Ara R, Brazier JE. Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value Health. 2011;14(4):539–545. doi: 10.1016/j.jval.2010.10.029.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Single technology appraisal (STA). Specification for manufacturer/sponsor submission of evidence. 2012 cited 2023 17 August 2023]. Available from: https://www.nice.org.uk/guidance/ta358/documents/kidney-disease-autosomal-dominant-polycystic-tolvaptan-id652-committee-papers2.
   Google Scholar
• Chung EY, Palmer SC, Saglimbene VM, et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2023;2(2):Cd010590.
   PubMedGoogle Scholar
• Jankowski J, Floege J, Fliser D, et al. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143(11):1157–1172. doi: 10.1161/CIRCULATIONAHA.120.050686.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013 [10 July 2023]. Available from: https://www.nice.org.uk/process/pmg9/chapter/the-appraisal-of-the-evidence-and-structured-decision-making.
   Google Scholar
• Alexandre AF, Morga A, Thomas C, et al. Preferences for anaemia treatment attributes among patients with non-dialysis-dependent chronic kidney disease. Adv Ther. 2023;40(2):641–657. doi: 10.1007/s12325-022-02367-z.
   PubMed Web of Science ®Google Scholar
• Theidel U, Asseburg C, Giannitsis E, et al. Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany. Clin Res Cardiol. 2013;102(6):447–458. doi: 10.1007/s00392-013-0552-7.
   PubMed Web of Science ®Google Scholar
• Lok CE, Bhola C, Croxford R, et al. Reducing vascular access morbidity: a comparative trial of two vascular access monitoring strategies. Nephrol Dial Transplant. 2003;18(6):1174–1180. doi: 10.1093/ndt/gfg122.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. British National Formulary. Epoetin alfa [10 July 2023]. Available from: https://bnf.nice.org.uk/medicinal-forms/epoetin-alfa.html.
   Google Scholar
• National Institute for Health and Care Excellence. British National Formulary. Darbepoetin alfa [10 July 2023]. Available from: https://bnf.nice.org.uk/medicinal-forms/darbepoetin-alfa.html.
   Google Scholar
• National Institute for Health and Care Excellence. British National Formulary. Epoetin beta [10 July 2023]. Available from: https://bnf.nice.org.uk/medicinal-forms/epoetin-beta.html.
   Google Scholar
• National Institute for Health and Care Excellence. British National Formulary. Epoetin zeta [10 July 2023]. Available from: https://bnf.nice.org.uk/medicinal-forms/epoetin-zeta.html.
   Google Scholar
• National Institute for Health and Care Excellence. British National Formulary. Methoxy polyethylene glycol-epoetin beta [10 July 2023]. Available from: https://bnf.nice.org.uk/medicinal-forms/methoxy-polyethylene-glycol-epoetin-beta.html.
   Google Scholar
• National Institute for Health and Care Excellence. Technology appraisal guidance [TA807]: Roxadustat for treating symptomatic anaemia in chronic kidney disease 2022 [10 July 2023]. Available from: https://www.nice.org.uk/guidance/ta807.
   Google Scholar
• Hu Z, Tao H, Shi A, et al. The efficacy and economic evaluation of roxadustat treatment for anemia in patients with kidney disease not receiving dialysis. Expert Rev Pharmacoecon Outcomes Res. 2020;20(4):411–418. doi: 10.1080/14737167.2020.1747436.
   PubMed Web of Science ®Google Scholar
• UK Renal Registry. 20th Annual Report of the Renal Association 2018 [10 July 2023]. Available from: https://ukkidney.org/sites/renal.org/files/publication/file-attachments/Full%20Annual-Report_0.pdf.
   Google Scholar
• NHS England. 2018/19 National Cost Collection Data Publication 2022 [10 July 2023]. Available from: https://www.england.nhs.uk/publication/2018-19-national-cost-collection-data-publication/.
   Google Scholar
• NHS Business Service Authority. Prescription Cost Analysis - England 2019 2021 [10 July 2023]. Available from: https://www.nhsbsa.nhs.uk/statistical-collections/prescription-cost-analysis/prescription-cost-analysis-england-2019.
   Google Scholar
• National Institute for Health and Care Excellence. British National Formulary 2023 [10 July 2023]. Available from: https://bnf.nice.org.uk/.
   Google Scholar
• National Institute for Health and Care Excellence. British National Formulary. Roxadustat [10 July 2023]. Available from: https://bnf.nice.org.uk/drugs/roxadustat/medicinal-forms/.
   Google Scholar
• Personal Social Services Research Unit. Unit Costs of Health and Social Care 2019 [10 July 2023]. Available from: https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2019/.
   Google Scholar
• Personal Social Services Research Unit. Unit Costs of Health and Social Care 2020 [10 July 2023]. Available from: https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2020/.
   Google Scholar
• National Institute for Health and Care Excellence. British National Formulary. Ferrous fumarate [10 July 2023]. Available from: https://bnf.nice.org.uk/medicinal-forms/ferrous-fumarate.html.
   Google Scholar
• National Institute for Health and Care Excellence. British National Formulary. Ferrous gluconate [10 July 2023]. Available from: https://bnf.nice.org.uk/medicinal-forms/ferrous-gluconate.html.
   Google Scholar
• National Institute for Health and Care Excellence. British National Formulary. Ferrous sulfate [10 July 2023]. Available from: https://bnf.nice.org.uk/medicinal-forms/ferrous-sulfate.html.
   Google Scholar
• National Institute for Health and Care Excellence. British National Formulary. Iron dextran [10 July 2023]. Available from: https://bnf.nice.org.uk/medicinal-forms/iron-dextran.html.
   Google Scholar
• National Institute for Health and Care Excellence. British National Formulary. Iron sucrose [10 July 2023]. Available from: https://bnf.nice.org.uk/medicinal-forms/iron-sucrose.html.
   Google Scholar
• National Institute for Health and Care Excellence. British National Formulary. Iron carboxymaltose [10 July 2023]. Available from: https://bnf.nice.org.uk/medicinal-forms/ferric-carboxymaltose.html.
   Google Scholar
• Xu XM, Vestesson E, Paley L, et al. The economic burden of stroke care in England, Wales and Northern Ireland: using a national stroke register to estimate and report patient-level health economic outcomes in stroke. Eur Stroke J. 2018;3(1):82–91. doi: 10.1177/2396987317746516.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Technology appraisal guidance [TA317]: Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes 2014 [10 July 2023]. Available from: https://www.nice.org.uk/guidance/ta317.
   Google Scholar